Zeta Acquisition Corp II

-

Stock Issuer and Owners

Home | Sign Up | Log In
Due Diligence for Asset Managers
Analyze the public filings of asset managers
Dive into the EDGAR, IAPD, CAFR source data
New Features
Latest Fund Raises
Related People
Fund Service Providers
Startup & Company Raises
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Keyboard
Zeta Acquisition Corp II
TickerWHWK
CIK #0001422142
CUSIP00032Q104
SectorReal Estate & Construction - Blank Checks
AddressEquity Dynamics Inc 666 Walnut Street Ste 2116, Des Moines, IA 50309
Source [EDGAR]
Reg D Offering (Form D) Filed Raised Terms
AADI Bioscience Inc 2025-03-18 100.0 M Exemption: 506(b) · Duration: One year or less · Commission: $4,335,553 · Revenue: Decline to Disclose
Aerpio Pharmaceuticals Inc 2017-03-30 41.8 M Exemption: 506(b) · Duration: One year or less · Commission: $4,229,507 · Revenue: Decline to Disclose
CIK Filing 2011 - 2026
[0001422142] 10-K
[0001422142] 10-Q
[0001422142] 3
[0001422142] 4
[0001422142] 5
[0001422142] 8-K
[0001422142] D
[0001422142] SC 13D
[0001422142] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
OrbiMed Advisors LLC Whitehawk Therapeutics Inc [2025-05-15] 0.0
Suvretta Capital Management LLC AADI Bioscience Inc [2025-03-11] 0.0
ABG Management Ltd AADI Bioscience Inc [2025-03-10] 0.0
QVT Financial LP AADI Bioscience Inc [2025-02-14] 0.0
BML Investment Partners LP AADI Bioscience Inc [2025-01-30] 0.0
Point72 Asset Management LP AADI Bioscience Inc [2025-01-29] 0.0
BML Investment Partners LP AADI Bioscience Inc [2024-12-31] 0.0
EcoR1 Capital LLC AADI Bioscience Inc [2024-09-03] 7.5
BML Investment Partners LP AADI Bioscience Inc [2024-08-28] 4.8
Satter Muneer A AADI Bioscience Inc [2022-10-04] 5.3
Venrock Healthcare Capital Partners II LP AADI Bioscience Inc [2022-02-14] 7.3
Desai Neil AADI Bioscience Inc [2021-09-08] 12.4
Biotechnology Value Fund L P AADI Bioscience Inc [2021-09-07] 2.9
Acuta Capital Partners LLC AADI Bioscience Inc [2021-09-07] 7.2
Vivo Panda LLC AADI Bioscience Inc [2021-09-02] 2.8
RA Capital Management LP Aerpio Pharmaceuticals Inc [2021-08-23] 5.22
RA Capital Management LP Aerpio Pharmaceuticals Inc [2021-07-12] 3.3
Avoro Capital Advisors LLC Aerpio Pharmaceuticals Inc [2021-06-04] 0.5
Point72 Asset Management LP Aerpio Pharmaceuticals Inc [2021-05-26] 3.9
Vanguard Group Inc Aerpio Pharmaceuticals Inc [2021-02-10] 5.76
Ikarian Capital LLC Aerpio Pharmaceuticals Inc [2021-01-11] 1.0
BML Investment Partners LP Aerpio Pharmaceuticals Inc [2020-03-09] 5.3
Kearny Venture Partners LP Aerpio Pharmaceuticals Inc [2017-03-28] 5.8
OrbiMed Advisors LLC Aerpio Pharmaceuticals Inc [2017-03-27] 16.3
Satter Muneer A Aerpio Pharmaceuticals Inc [2017-03-27] 12.0
Novartis BioVentures Ltd Aerpio Pharmaceuticals Inc [2017-03-27] 21.5
Venture Investors Early Stage Fund IV LP Aerpio Pharmaceuticals Inc [2017-03-27] 5.8
Form 3/4/5 Filer 2011 - 2026
Castelein Caley
Zeta Acquisition Corp II
Desai Neil
Maroun Richard E
Zhao Baiteng
Hirmand Mohammad
Reeve Emma
Avoro Ventures LLC
Aghazadeh Behzad
Avoro Capital Advisors LLC
Giacobello Scott M
Dugan Margaret
Ball Bryan
Lennon David James
Dornan David
Dalal Anupam
Hehenberger Karin M
ITRI Lorettta M
Delaney Brendan
Thibault Lance E
Cohen Cheryl
Dugel Pravin
Prelack Steven
OrbiMed Advisors LLC
OrbiMed Capital GP V LLC
Marek Regina
Peters Kevin G
Gardner Joseph H
Khuong Chau Quang
Satter Muneer A
Rogers Michael W
Hoffman Stephen J
Novartis AG
Novartis BioVentures Ltd
Pakola Steve
Desai Dhaval
Weiss Paul M
Murphy James B
Isaly Samuel D
Insider Transaction (Form 3/4/5) Date Action Shares Price Value ($)
Giacobello Scott M
Common Stock
2026-03-02 Sell 2,594 $3.31 8,586
Lennon David James
Common Stock
2026-03-02 Sell 5,100 $3.31 16,881
Ball Bryan
Common Stock
2026-03-02 Sell 1,834 $3.31 6,071
Ball Bryan
Common Stock
2026-03-01 Option exercise 5,000
Giacobello Scott M
Restricted Stock Units · derivative
2026-03-01 Option exercise 6,750 $0.00
Ball Bryan
Restricted Stock Units · derivative
2026-03-01 Option exercise 5,000 $0.00
Lennon David James
Restricted Stock Units · derivative
2026-03-01 Option exercise 16,250 $0.00
Giacobello Scott M
Common Stock
2026-03-01 Option exercise 6,750
Lennon David James
Common Stock
2026-03-01 Option exercise 16,250
Dugan Margaret
Restricted Stock Units · derivative
2025-12-01 Grant 55,309 $0.00
Dugan Margaret
Stock option (right to buy) · derivative
2025-12-01 Grant 650,000 $0.00
Zhao Baiteng
Stock Option (right to buy) · derivative
2025-06-17 Grant 40,006 $0.00
Reeve Emma
Stock Option (right to buy) · derivative
2025-06-12 Grant 40,006 $0.00
Desai Neil
Stock Option (right to buy) · derivative
2025-06-12 Grant 40,006 $0.00
Hirmand Mohammad
Stock Option (right to buy) · derivative
2025-06-12 Grant 40,006 $0.00
Maroun Richard E
Stock Option (right to buy) · derivative
2025-06-12 Grant 40,006 $0.00
Castelein Caley
Stock Option (right to buy) · derivative
2025-06-12 Grant 40,006 $0.00
Dalal Anupam
Stock Option (right to buy) · derivative
2025-06-12 Grant 40,006 $0.00
Avoro Ventures LLC +2
Stock Option (right to buy) · derivative
2025-06-12 Grant 40,006 $0.00
Ball Bryan
Restricted Stock Units · derivative
2025-04-01 Grant 366,532 $0.00
showing 20 of 200 most recent transactions
13F Ownership Over TimeHoldersShares Held
2026-03-31 62 35,208,927
2025-12-31 48 32,977,502
2025-09-30 41 28,831,851
2025-06-30 40 29,433,079
2025-03-31 51 31,815,151
2024-12-31 54 14,983,187
2024-09-30 53 12,003,038
2024-06-30 66 11,483,327
2024-03-31 61 14,151,406
2023-12-31 66 13,314,097
2023-09-30 74 14,471,939
2023-06-30 68 14,071,864
Form 13F Holdings
Firm Period DFND Voting Shares
Y-Intercept Hong Kong Ltd [2026-06-30] SOLE 24,363 24,363
Prev | Page 1 | Next
Terms | Privacy | Providers | Companies | Guide
tony@aum13f.com